Revance Therapeutics (RVNC) Statistics

Revance Therapeutics Inc (RVNC) is a biotechnology company focused on developing and commercializing innovative therapies for aesthetic and therapeutic indications. The company's primary product candidate is DaxibotulinumtoxinA, a neuromodulator that has the potential to be used in a variety of therapeutic and aesthetic indications. Revance's stock statistics show that it has a market capitalization of $2.5 billion, with a current share price of $32.50. The company's valuation metrics indicate a price to sales ratio of 15.8 and a price to book ratio of 4.2. These metrics suggest that the stock may be relatively undervalued compared to its peers in the biotechnology sector.

In terms of fundamentals, Revance Therapeutics Inc has demonstrated strong revenue growth over the past few years. The company's revenue per share has increased from $0.23 in 2016 to $1.47 in 2020, representing a compound annual growth rate of 43%. This impressive growth is driven by the company's focus on developing a robust pipeline of innovative products. Revance's enterprise to EBITDA ratio stands at 96.2, indicating that the company may have a relatively high level of debt. However, its profit margin is 78.5%, demonstrating its ability to generate significant profits from its operations. In addition, Revance Therapeutics Inc has a total debt of $239.2 million, which represents a relatively low debt burden compared to its market capitalization.